MRI-Guided radiation: a sharper weapon against gynecologic cancer?
NCT ID NCT03277469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests new MRI-based tools to make brachytherapy—a type of internal radiation—more accurate for gynecologic cancer. Researchers will compare standard brachytherapy with an MRI-guided version in 49 patients to see if it improves radiation delivery. The goal is better tumor control and fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- brachytherapy (internal radiation therapy)
- What this could lead to
- If successful, this could make brachytherapy more precise, potentially improving tumor control and reducing side effects for gynecologic cancer patients.
- What could go wrong
- This is a small, early-stage study (49 participants) focused on technique optimization, not a direct test of cure. Results may not apply to all patients or cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
49 people
The number who actually took part.
- Started
-
Nov 2017
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. * Participants must have a biopsy-proven diagnosis of primary or recurrent gynecologic cancer for which intracavitary or interstitial brachytherapy is planned as standard treatment. Eligible disease sites include primary or recurrent cancer of endometrial, ovarian, cervical, vaginal, or vulvar origin. * Age of 18 years or older are eligible. * ECOG performance status of 2 or less. * Patients who have received prior radiation or chemotherapy may be enrolled on this study. * Participant is deemed to be an appropriate candidate for MRI-guided brachytherapy by the radiation oncologist and the patient elects to be treated with MRI-guided brachytherapy. * Participant provides informed consent for prospective collection of relevant medical records for analysis of clinical outcome and treatment-planning techniques. Exclusion Criteria: * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, interstitial lung disease, active peptic ulcer disease or gastritis, active bleeding diatheses, serious chronic gastrointestinal conditions associated with diarrhea or psychiatric illness/social situations that would limit compliance with study requirements. * Contraindication to MRI identified by the MR procedure screening form, such as a pacemaker, aneurysm clip, inner ear implant, neurostimulator, or other non-MR compatible implant or device.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gynecologic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Vitamin d gel on the scalp: a new hope against chemo hair loss?
- Can a personalized exercise program boost recovery in cancer survivors?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Braids and conditioner may boost scalp cooling against chemo hair loss
- New imaging tool could help surgeons detect hidden cancer cells during surgery
- Could an ALS drug clear the fog of chemo brain?